Evidence map›Paper›PMID 40302103›Full record

ArticleAmerican journal of epidemiology2026

Long-term performance of the Gleason score in predicting metastatic and fatal prostate cancer.

Zhike Lin, Konrad H Stopsack, Michelangelo Fiorentino, J Bailey Vaselkiv, Travis Gerke, Andreas Pettersson, Richard Flavin, Sinead Flanagan, Philip W Kantoff, Tamara L Lotan and 5 more

Abstract read
In one paragraph

Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhike LinDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0009-0008-3549-9688
Konrad H StopsackDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0002-0722-1311
Michelangelo FiorentinoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0002-1749-150X
J Bailey VaselkivDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0001-7702-9504
Travis GerkeProstate Cancer Clinical Trials Consortium, New York, NY, United States.ORCID 0000-0002-9500-8907
Andreas PetterssonClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-3316-045X
Richard FlavinDepartment of Pathology, Trinity College, Dublin, Ireland.ORCID 0000-0002-4993-4563
Sinead FlanaganDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0001-8690-792X
Philip W KantoffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.ORCID 0000-0001-7275-0597
Tamara L LotanDepartment of Pathology, Johns Hopkins University, Baltimore, MD, United States.ORCID 0000-0002-0494-9067
Mark A PrestonDepartment of Urology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Stephen P FinnDepartment of Pathology, Trinity College, Dublin, Ireland.ORCID 0000-0002-8628-5814
Massimo LodaDepartment of Pathology, Weill Cornell, New York, NY, United States.ORCID 0000-0001-9674-8379
Kathryn L PenneyDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0002-2815-3450
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0002-2551-4927

Funding

Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI BALK, STEVEN P., BELTRAN, HIMISHA · 2002 to 2017
$36.2M
Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
The Impact of DNA Damage Repair Abnormalities in Prostate CancerP01CA228696 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI OFFIT, KENNETH, POMERANTZ, MARK M. · 2019 to 2024
$8.7M
Comprehensive characterization of prostate stromal gene expression and association with lethal prostate cancerR37CA227190 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BIRMANN, BRENDA M, TYEKUCHEVA, SVITLANA · 2018 to 2024
$3.6M
NCI NIH HHS P01 CA228696NCI NIH HHS P50 CA090381NCI NIH HHS R37 CA227190NCI NIH HHS U01 CA167552Zhu Family Center for Global Cancer Prevention
6 · The paper itself

Abstract

The time dependence in the performance of prognostic factors for cancer survival is typically incompletely understood, including in prostate cancer. We applied a "cumulative/dynamic" time-varying area under the curve (tAUC) for cumulative incidence of lethal prostate cancer (metastases/cancer-specific death). In two prospective prostate cancer patient cohorts followed for lethal outcomes after radical prostatectomy, genitourinary pathologists undertook a histopathologic review of tumor specimens to assign Gleason grade groups 1-5, a known strong short-term prognostic factor. Among 1490 patients, 144 lethal events occurred during 35 years of follow-up (median, 18). The 10-year risk of lethal disease was 2% (95% CI, 1-3) for grade group 2 and 21% (95% CI, 16-28) for grade group 5 cancers. By 25 years, risks were 5% (95% CI, 3-8) and 32% (95% CI, 26-41), respectively. Prediction accuracy was strongest over the first 10 years (tAUC 0.83 [95% CI, 0.79-0.86]) but remained informative for 25 years (tAUC 0.76 [95% CI, 0.70-0.81]), including among long-term metastasis-free survivors. Risk-based AUCs instead of hazard-based "incident/dynamic" AUCs allowed for interpretable characterization of prognostic accuracy over well-defined time periods. Lethal progression of high-grade prostate cancer occurred predominantly early, while that of lower grade tumors accumulated over decades after surgery.

Indexed as

Neoplasm GradingProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProspective StudiesProstatectomyTime Factorsabsolute riskGleason scoremetastasisprognosisprostate cancertime-varying area under the curve

Identifiers

PMID40302103
PMCPMC13066330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.